Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -20.89% is 66% below its 5-year average of -12.60%, near the low end of its 5-year range (-38.07%–26.44%).
378.91% below its 12-month average of 7.49%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.42%.
RETURN ON ASSETS (ROA)
-20.89%
RETURN ON ASSETS (ROA) AVG TTM
7.49%
RETURN ON ASSETS (ROA) AVG 3Y
-5.84%
RETURN ON ASSETS (ROA) AVG 5Y
-12.60%
RETURN ON ASSETS (ROA) AVG 10Y
-16.58%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-378.91%
CURRENT VS 3Y AVG
-257.55%
CURRENT VS 5Y AVG
-65.84%
CURRENT VS 10Y AVG
-25.97%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
+16.27%
vs the sector median at left
CytomX Therapeutics, Inc.
Market Cap
$561.67M
Return on Assets (ROA)
-20.89%
TTM Avg
7.49%
3Y Avg
-5.84%
5Y Avg
-12.60%
Market Cap
$569.56M
Return on Assets (ROA)
20.70%
TTM Avg
2.32%
3Y Avg
-24.93%
5Y Avg
-30.88%
Market Cap
$551.09M
Return on Assets (ROA)
-16.69%
TTM Avg
-61.13%
3Y Avg
-63.72%
5Y Avg
-100.27%
Market Cap
$573.38M
Return on Assets (ROA)
-59.22%
TTM Avg
-47.88%
3Y Avg
-51.20%
5Y Avg
-67.88%
Market Cap
$547.86M
Return on Assets (ROA)
0.39%
TTM Avg
-16.14%
3Y Avg
-90.03%
5Y Avg
-84.55%
Market Cap
$579.88M
Return on Assets (ROA)
-37.16%
TTM Avg
-32.95%
3Y Avg
-32.95%
5Y Avg
-32.95%
Market Cap
$596.36M
Return on Assets (ROA)
-42.15%
TTM Avg
-50.20%
3Y Avg
-44.84%
5Y Avg
-47.93%
Market Cap
$519.25M
Return on Assets (ROA)
-17.40%
TTM Avg
-49.85%
3Y Avg
-45.66%
5Y Avg
-41.17%
Market Cap
$517.79M
Return on Assets (ROA)
-89.18%
TTM Avg
-100.15%
3Y Avg
-92.96%
5Y Avg
-79.13%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | $561.67M | -20.89% | 7.49% | -5.84% | -12.60% |
| CorMedix Inc. (CRMD)vs › | $569.56M | 20.70% | 2.32% | -24.93% | -30.88% |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | -16.69% | -61.13% | -63.72% | -100.27% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | -59.22% | -47.88% | -51.20% | -67.88% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 0.39% | -16.14% | -90.03% | -84.55% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $579.88M | -37.16% | -32.95% | -32.95% | -32.95% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | -42.15% | -50.20% | -44.84% | -47.93% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -17.40% | -49.85% | -45.66% | -41.17% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -89.18% | -100.15% | -92.96% | -79.13% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -30.08% | -46.42% | -46.30% | -37.15% |
ROA
-20.9%
ROE
-26.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -11.46% |
| 2024-12-31 | 26.44% |
| 2023-12-31 | -0.28% |
| 2022-12-31 | -38.07% |
| 2021-12-31 | -34.14% |
| 2020-12-31 | -18.07% |
| 2019-12-31 | -29.96% |
| 2018-12-31 | -18.51% |
| 2017-12-31 | -10.84% |
| 2016-12-31 | -29.58% |
| 2015-12-31 | -17.94% |
| 2014-12-31 | -41.49% |
| 2013-12-31 | -106.77% |
